# Akebia Therapeutics clinical trials: 37 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials with Akebia Therapeutics as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Akebia Therapeutics: 37 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/akebia-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 24, 2026 | NCT07429006 | SAD and MAD Study of AKB-9090 in Healthy Adult Participants | Akebia Therapeutics | Phase 1 | Recruiting | Healthy Volunteers | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07429006) |
| December 8, 2025 | NCT07268638 | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) | Akebia Therapeutics | Phase 2 | Recruiting | Focal Segmental Glomerulosclerosis | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07268638) |
| March 30, 2025 | NCT06901505 | To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving... | Akebia Therapeutics | Phase 3 | Completed | Anemia of Chronic Kidney Disease | 353 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06901505) |
| May 17, 2024 | NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | Akebia Therapeutics | Phase 2 | Recruiting | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419205) |
| October 19, 2021 | NCT05082584 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to... | Akebia Therapeutics | Phase 3 | Withdrawn | Anemia of Chronic Kidney Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05082584) |
| October 19, 2021 | NCT05082571 | Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease | Akebia Therapeutics | Phase 3 | Withdrawn | Anemia of Chronic Kidney Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05082571) |
| January 13, 2021 | NCT04707768 | Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times... | Akebia Therapeutics | Phase 3 | Completed | Anemia Associated With Chronic Kidney Disease (CKD) | 456 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04707768) |
| January 13, 2021 | NCT04707573 | Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4 | Akebia Therapeutics | Phase 2 | Completed | Chronic Kidney Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04707573) |
| March 18, 2020 | NCT04313153 | Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of... | Akebia Therapeutics | Phase 3 | Completed | Anemia | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04313153) |
| March 9, 2020 | NCT04299633 | Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat | Akebia Therapeutics | Phase 1 | Completed | Healthy Volunteers | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04299633) |
| June 19, 2019 | NCT03992066 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With... | Akebia Therapeutics | Phase 1 | Completed | Anemia Associated With Chronic Kidney Disease | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992066) |
| January 11, 2019 | NCT03801759 | Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide | Akebia Therapeutics | Phase 1 | Completed | Drug Interaction Potentiation | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03801759) |
| January 11, 2019 | NCT03801746 | Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin | Akebia Therapeutics | Phase 1 | Completed | Drug Interaction Potentiation | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03801746) |
| January 11, 2019 | NCT03801733 | Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin | Akebia Therapeutics | Phase 1 | Completed | Drug Interaction Potentiation | 134 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03801733) |
| January 10, 2019 | NCT03799848 | A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function | Akebia Therapeutics | Phase 1 | Completed | Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03799848) |
| January 10, 2019 | NCT03799627 | Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa | Akebia Therapeutics | Phase 2 | Completed | Anemia, Dialysis-dependent Chronic Kidney Disease | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03799627) |
| December 28, 2018 | NCT03789032 | Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat | Akebia Therapeutics | Phase 1 | Completed | Drug Interaction Potentiation, Pharmacokinetics | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03789032) |
| September 5, 2018 | NCT03657290 | A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG... | Akebia Therapeutics | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03657290) |
| August 21, 2018 | NCT03639155 | A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults | Akebia Therapeutics | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03639155) |
| August 18, 2017 | NCT03254485 | A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) | Akebia Therapeutics | Phase 2 | Completed | Heart Failure With Preserved Ejection Fraction | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03254485) |
| August 8, 2017 | NCT03242967 | Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney... | Akebia Therapeutics | Phase 3 | Withdrawn | Anemia, Dialysis-Dependent Chronic Kidney Disease | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03242967) |
| July 14, 2017 | NCT03217591 | A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by... | Akebia Therapeutics | Phase 2 | Completed | Type 2 Diabetes Mellitus With Diabetic Nephropathy | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03217591) |
| May 4, 2017 | NCT03140722 | Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to... | Akebia Therapeutics | Phase 2 | Terminated | Anemia, Dialysis-Dependent Chronic Kidney Disease | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03140722) |
| February 15, 2017 | NCT03054350 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD) | Akebia Therapeutics | Phase 2 | Completed | Anemia, Dialysis Dependent Chronic Kidney Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03054350) |
| February 15, 2017 | NCT03054337 | Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) | Akebia Therapeutics | Phase 2 | Completed | Anemia, Non-dialysis Dependent Chronic Kidney Disease | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03054337) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 2 | 13 |
| Phase 3 | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 30 |
| Recruiting | 3 |
| Withdrawn | 3 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia | 21 |
| Renal Insufficiency, Chronic | 19 |
| Renal Insufficiency | 11 |
| Kidney Diseases | 4 |
| Kidney Failure, Chronic | 3 |
| Glomerulonephritis, IGA | 1 |
| Lupus Nephritis | 1 |
| Complement Component 3 Deficiency, Autosomal Recessive | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Proteinuria | 1 |
| Heart Failure | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Business office supplies and stationery companies in the United States](https://specstream.ai/data/businesses/business-office-supplies-and-stationery-companies/united-states)
- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Geological services in the United States](https://specstream.ai/data/businesses/geological-services/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Packing supply stores in the United States](https://specstream.ai/data/businesses/packing-supply-stores/united-states)
- [Road contractors in the United States](https://specstream.ai/data/businesses/road-contractors/united-states)
